NL-OMON50988招募中2 期
HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study) - HYPNO-trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Biochemical recurrent prostate adenocarcinoma after radical prostatectomy.
- •- PSA level >= 0.2 ng/ml
- •- No macroscopic disease on PSMA-PET/CT
- •- No local recurrence on MRI.
- •- <= 4 foci harbouring regional lymph node metastases (up to 6 nodes in total)
- •on nano-MRI (below aortic bifurcation).
排除标准
- •- If any of the abovementioned does not apply.
- •- Concurrent or previous androgen deprivation therapy.
- •- Previous pelvic radiotherapy.
- •- Active inflammatory bowel disease (Crohn*s disease or ulcerative colitis).
- •- Contraindication for MR-imaging according to local Radiology protocol or
- •unable to undergo MR-linac treatment (e.g. due to claustrophobia or body
- •circumference).
- •- Ferro-magnetic objects in the pelvis or hip causing disturbing susceptibility
- •artifacts (at the discretions of the radiologist).
- •- Inability to give informed consent.
研究者
相似试验
进行中（未招募）
1 期
MRI-guided irradiation of prostate cancer lymph node metastases identified by nano-MRI.EUCTR2021-003779-32-NLRadboud University Medical Center20
已完成
2 期
Hypofractionated stereotactic radiotherapy for large brain metastasesBrain metastasesJPRN-UMIN000010112Department of Radiology, Nagoya City University Graduate School of Medical Sciences90
已完成
1 期
Hypofractionated radiotherapy for low and intermediate-risk prostate cancer using robot-tracking stereotactic radiotherapy -phase I/II clinical trialprostate cancerJPRN-UMIN000014328Osaka University Graduate School of Medicine75
招募中
3 期
Standard moderately hypofractionated radiotherapy vs. ultra-hypofractionated focal lesion ablative microboost in prostate cancer, Hypo-FLAME 3.010038597prostate cancerNL-OMON56327Antoni van Leeuwenhoek Ziekenhuis352
进行中（未招募）
不适用
Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancerKCT0005443ational Cancer Center35